Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Financing Activities (2021 - 2025)

Journey Medical (DERM) has disclosed Cash from Financing Activities for 5 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 2493.88% year-over-year to $7.0 million, compared with a TTM value of $21.4 million through Sep 2025, down 16.28%, and an annual FY2024 reading of $17.0 million, up 453.73% over the prior year.
  • Cash from Financing Activities was $7.0 million for Q3 2025 at Journey Medical, up from $165000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $31.8 million in Q4 2021 and bottomed at -$13.1 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $4.9 million, with a median of $3.6 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities plummeted 11890.99% in 2023, then skyrocketed 3048.08% in 2024.
  • Year by year, Cash from Financing Activities stood at $31.8 million in 2021, then tumbled by 97.02% to $948000.0 in 2022, then surged by 1926.37% to $19.2 million in 2023, then tumbled by 44.72% to $10.6 million in 2024, then tumbled by 33.72% to $7.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for DERM at $7.0 million in Q3 2025, $165000.0 in Q2 2025, and $3.6 million in Q1 2025.